Newcastle disease virus (NDV) oncolysis is believed to be facilitated by a defective Type I interferon (IFN) response. We compared hepatocellular carcinoma (HCC)-derived cell lines and found that TRAILresistant cells were more susceptible to NDV oncolysis than were TRAIL-sensitive cells. In examining the IFN response, we found that basal expression of the IFN-stimulated gene (ISG)-12a was low in TRAILresistant but high in TRAIL-sensitive cells, and ISG12a over-expression or silencing enhanced or reduced their TRAIL sensitivities, respectively. Moreover, ISG12a over-expression in TRAIL-resistant cells decreased NDV replication but surprisingly increased oncolysis while ISG12a silencing had the opposite effect on TRAIL-sensitive cells. Finally, RIG-I and Noxa appear to also contribute to NDV oncolysis. Together, these results suggest that high basal ISG12a may inhibit NDV replication and oncolysis, while low basal ISG12a may allow sufficient NDV replication for induction of ISG12a, and other factors required for NDV oncolysis, with implications for future therapeutics.
Introduction
Hepatocellular carcinoma (HCC) is among the main causes of cancer-related deaths worldwide (Jemal et al., 2011) . Only a small percentage of patients respond to current treatments including surgery, chemotherapy and radiotherapy. New therapeutic strategies are needed for cancer treatment.
Newcastle disease virus (NDV) is a negative-strand RNA virus possessing oncolytic activities and has been used as an oncolytic agent in clinical trials in various human cancers (Shobana et al., 2013; Zamarin and Palese, 2012) . In phase 1 trail, oncolytic strain of NDV PV701 displays intravenous efficacy. This oncolytic virus displays a broad spectrum of anti-tumor activity in vitro and in vivo (Lorence et al., 2007) . In another phase I/II trial, intravenous NDV-HUJ (OV001) is well tolerated in recurrent glioblastoma multiforme (Freeman et al., 2006) . Altomonte et al. reported a novel NDV vector harboring an L289A mutation within the F gene, which resulted in enhanced fusion and cytotoxicity of hepatocellular carcinoma (HCC) cells in vitro (Altomonte et al., 2010) . NDV has been shown to selectively replicate in cancer cells and damage them, while sparing normal cells, a property believed to be due to a defective interferon (IFN) response in cancer cells (Fiola et al., 2006) . Normal cells, which are capable of initiating robust antiviral responses quickly after infection, can inhibit viral replication before cell death can be initiated. The sensitivity of NDV to IFN, coupled with defective IFN signaling pathway in cancer cells, facilitates NDV replication in the cells and increases their destruction (Park et al., 2003) .
ISG12a (interferon-stimulated gene 12a, interferon alphainducible protein 27) is highly induced by type I IFN in many cell types (Cheriyath et al., 2011) . It has been reported that inhibition of ISG12a expression prevents the sensitization to etoposideinduced apoptosis (Rosebeck and Leaman, 2008) . Whether ISG12a is involved in NDV oncolysis is unclear. Many antitumor agents cause apoptosis of tumor cells and resistance to these agents is due to antiapoptotic protein overexpression or downregulation of the proapoptotic proteins (Gyrd-Hansen and Meier, 2011) .
NDV exerts its oncolytic activity in infected cells through apoptosis induction. NDV induces apoptosis through activating the mitochondrial-dependent pathway (Elankumaran et al., 2006) . For the mitochondria-dependent pathway, oligomerization of Bax results in the release of cytochrome c and caspase-9 activation. Activated caspase-3 and caspase-7 provoke cellular destruction by cleaving several hundred cellular proteins including poly ADPribose polymerase (PARP) (van Gurp et al., 2003) . Ectopic expression of Noxa enhanced viral-induced apoptosis, typified by enhanced cytochrome c release from mitochondrial to the cytosolic fraction and increased cleavage of caspases 3 and 9 (Sun and Leaman, 2005) . Self-sacrifice of cells limits the spread of infection and hinders the NDV oncolysis if the virus is present at pretty low level.
One study demonstrated the enhanced oncolytic activity of attenuated isolate of NDV (HUJ) undergoing one cycle of replication in therapy-resistant primary melanoma cells expressing Livin and the cells have an IFN response (Lazar et al., 2010) . A similar mechanism was suggested in another study which showed enhanced oncolytic activity of engineered NDV expressing NS1 gene of influenza A in apoptosis-resistant human non-small-cell lung cancer cell line overexpressing Bcl-xL (Mansour et al., 2011) . These findings indicated that the anti-apoptotic effect of antiapoptotic proteins might prolong the cancer cell survival and allow the virus to replicate efficiently. Whether selective replication of NDV in liver cancer cells is due to defective apoptotic signaling or IFN response will be addressed in the study. A recent study reported that increased malignancy of cancer cells compared with less malignant cells correlates with enhanced NDV sensitivity (Puhlmann et al., 2010) . Whether NDV sensitivity correlates with HCC progression will also be studied in this paper.
To address these questions, we used TRAIL-sensitive welldifferentiated HCC cell lines LH86, HLCZ03 and TRAIL-resistant advanced HCC cell lines Huh7 and HLCZ01. We demonstrated that the oncolytic effect of NDV is enhanced in apoptosis-resistant cancer cells. ISG12a contributes to inhibition of viral replication and NDV oncolysis in cancer cells through RIG-I. Induction of Noxa by NDV contributes to ISG12a-mediated oncolysis.
Results

The different sensitivity of HCC cell lines to TRAIL
To better understand the mechanisms of NDV oncolysis, we have attempted to develop HCC cells using liver tumor tissue samples. We established a novel HCC cell line HLCZ03. The cells were derived from well-differentiated HCC tissue of a male patient. The morphology of HLCZ03 cells is shown in Fig. 1A . The cells express the human liver-specific gene and protein albumin (Fig. 1B and C, respectively) .
We examined the TRAIL sensitivity of different human HCC cell lines LH86, Huh7, HLCZ01 and HLCZ03. The cells were exposed to TRAIL for 4 h. The cleaved PARP in LH86 and HLCZ03 cells could be easily detected by western blot (Fig. 1D) . Flow cytometry data showed that well-differentiated LH86 and HLCZ03 cells underwent apoptosis whereas advanced Huh7 and HLCZ01 cells displayed resistance to TRAIL-induced apoptosis (Fig. 1E) . We then tested the cytotoxicity of celecoxib to these HCC cells. Huh7 and HLCZ01 cells were also resistant to celecoxib compared to LH86 and HLCZ03 cells (Fig. 1F) . These results suggested that Huh7 and HLCZ01 cells might be more resistant to anti-cancer drug-induced apoptosis.
NDV preferentially induces oncolysis in apoptosis-resistant advanced cancer cells
Better understanding the mechanisms of NDV oncolysis will extend our knowledge of this novel anti-tumor strategy and lead to the successful use of the virus. We used NDV to infect TRAILresistant Huh7 and HLCZ01 cells and sensitive LH86 and HLCZ03 cells and compared the oncolytic activity of NDV in the cells. Cytotoxicity was measured at 48 h postinfection (pi) by MTS assay. Despite an apoptotic resistance, we observed stronger oncolytic activity of NDV in TRAIL-resistant Huh7 and HLCZ01 cells than in TRAIL-sensitive LH86 and HLCZ03 cells. NDV levels were also higher in Huh7 and HLCZ01 cells than in LH86 and HLCZ03 cells ( Fig. 2A) . The cell cultures were photographed under light microscope at 48 h pi to document the NDV oncolysis in the cells (Fig. 2B ). When we pretreated Huh7 cells with Z-VAD-FMK for 1 h and infected the cells with NDV, we observed higher oncolytic activity and enhanced replication of NDV in Huh7 cells pretreated with Z-VAD-FMK than in non-treated cells (Fig. 2C and D) . To further evaluate the potential oncolytic activity of NDV in vivo, we tested it in a liver cancer model. Nude mice were injected with Huh7, HLCZ01, LH86 and HLCZ03 cells to develop primary tumor. Fourteen days post-tumor implantation, mice were injected with NDV via i.v. and the control group was injected with PBS. The data showed that the cytotoxic effect of NDV in Huh7 and HLCZ01 cell-injected mice was higher than in LH86 and HLCZ03 cell-injected mice (Fig. 2E) . These results indicated that NDV preferentially infects apoptosis-resistant cells and induces oncolysis.
NDV overcomes resistance to apoptosis in Cancer cells
As the apoptosis-resistant cells are more susceptible to the oncolytic activity of NDV, we hypothesized whether resistance of cancer cells to apoptosis may be responsible for the enhanced viral replication. To compare apoptosis induction by NDV in Huh7, HLCZ01, HLCZ03 and LH86 cells, all the cells were infected with NDV and cleaved PARP was detected by western blot. Cleaved PARP could be easily detected in Huh7 and HLCZ01 cells at 48 h pi, and only slightly in LH86 and HLCZ03 cells at 72 h pi (Fig. 3A) . Interestingly, Huh7 and HLCZ01 cells showed an increased caspase-3/7 activity, with a peak at 48 h pi (Fig. 3B) . To examine whether the enhanced caspase-3/7 activity was associated with an increased number of cells undergoing apoptosis, we examined the percentage of apoptotic cells using flow cytometry. NDV induced an increased number of cells undergoing apoptosis in Huh7 and HLCZ01 cells compared to LH86 and HLCZ03 cells at 48 h pi (Fig. 3C) , suggesting that the increased number of apoptotic Huh7 and HLCZ01 cells is responsible for the enhanced caspase-3/7 activity.
ISG12a contributes to TRAIL sensitivity and is induced by NDV in HCC cells
To identify a possible correlation between ISG12a expression and HCC progression, ISG12a mRNA levels were determined in normal tissues (N11-N19), well-differentiated liver tissues (T19-T25, grades I and II, data not shown), and advanced liver tissues (T11-T18, grades III and IV, data not shown). There was an inverse correlation between the basal expression of ISG12a and HCC progression (Fig. 4A) . Our data showed that ISG12a overexpression in TRAIL-resistant Huh7 cells increased their sensitivity to TRAIL treatment while ISG12a silencing in TRAIL-sensitive LH86 cells increased their TRAIL resistance (Fig. 4B) , indicating that ISG12a contributes to TRAIL sensitivity. Indeed, the level of endogenous ISG12a was higher in well-differentiated LH86 and HLCZ03 cells than in advanced Huh7 and HLCZ01 cells (Fig. 4C) . However, NDV induced higher level of ISG12a in Huh7 and HLCZ01 cells than in LH86 and HLCZ03 cells after 48 h pi (Fig. 4C) , which was coupled with the enhanced NDV oncolysis in Huh7 and HLCZ01 cells compared to LH86 and HLCZ03 cells ( Fig. 2A) .
It is possible that NDV preferentially infects and lyses advanced cancer cells over well-differentiated cancer cells. So we compared the viral RNA level in different cells. Viral RNA level was higher in Huh7 and HLCZ01 cells than in LH86 and HLCZ03 cells at late time points (Fig. 4D) . To rule out the possibility that the enhanced NDV replication in Huh7 and HLCZ01 cells is due to the increased cellular permissibility to initial virus inoculation, the cells were infected with NDV at an MOI of 0.01 and the viral titer was monitored at 1 and 2 h pi. There was no marked difference of vial RNA level between these cells at these time points (Fig. 4D ). The data suggested that increased cellular permissibility to initial virus inoculation is not responsible for the enhanced oncolytic activity in advanced cancer cells.
NDV infection triggers less innate immune response in Cancer cells compared to normal primary Human hepatocytes (PHH)
Selective NDV replication in cancer cells has been associated with a defective innate response in these cells (Fiola et al., 2006) . To examine whether NDV infection induces type I IFN in liver cancer cells, we used NDV to infect PHH, Huh7, LH86, HLCZ01 and HLCZ03 cells and compared IFN-β level in these cells. Interestingly, although the induction of IFN-β was lower in Huh7 and HLCZ01 cells than in LH86 and HLCZ03 cells at early time points, it was markedly higher in Huh7 and HLCZ01 compared to LH86 and HLCZ03 after 48 h pi (Fig. 5A ). However, cancer cells showed reduced IFN induction compared with normal primary human hepatocytes (PHHs) (Fig. 5A ). To demonstrate whether IFN produced inhibits NDV replication, PHH, Huh7 and HLCZ01 cells were infected with NDV at an MOI of 0.01. The supernatant was collected 24 h pi and the virus present in the supernatant was UV inactivated. Naïve Huh7, LH86, HLCZ01 and HLCZ03 cells were treated with the inactivated supernatant and infected with NDV. The data demonstrated that supernatant in PHH and cancer cells inhibited viral replication (Fig. 5B) , consistent with predicted effects of induced IFN. Moreover, cancer cells showed a reduced response compared with PHH ( Fig. 5B ). To further examine whether IFN signaling pathway is functional in the cells, we treated PHH, Huh7, HLCZ01, LH86 and HLCZ03 cells with recombinant IFN-α. Twenty-four hours after treatment, the cells were infected with NDV. Exogenous IFN inhibited viral replication in normal and cancer cells (Fig. 5C ). There was less IFN response in cancer cells than that in normal cells (Fig. 5C ). To further confirm that IFN signaling pathway is functional in the cells, we knocked down IFN receptor in the four cell lines. Downregulation of IFNR suppressed the antiviral effect of IFN on NDV replication (Fig. 5D ). These results indicate that IFN responsiveness is important to 
ISG12a inhibits virus replication and contributes to the oncolytic effect of NDV in cancer cells
To demonstrate whether ISG12a is a mediator of NDV oncolysis, we delivered ISG12a into advanced Huh7 and HLCZ01 cells and analyzed the viral replication and oncolysis of NDV. Forced expression of ISG12a in Huh7 and HLCZ01 cells was confirmed by western blot using mouse anti-V5 antibody (Fig. 6A) . ISG12a over-expression in Huh7 and HLCZ01 cells inhibited NDV replication (Fig. 6B) . Surprisingly, NDV oncolysis was higher in Huh7 and HLCZ01 cells overexpressing ISG12a compared to that in the control cells while forced expression of ISG12a in Huh7 and HLCZ01 cells had a smaller effect on cell viability in the absence of viral infection (Fig. 6C) .
To further reveal that NDV oncolysis is related to ISG12a, we knocked down ISG12a in well-differentiated LH86 and HLCZ03 cells and analyzed the viral replication and NDV oncolysis. As shown in Fig. 6D , ISG12a is knocked down by shRNAs targeting ISG12a mRNA in LH86 and HLCZ03 cells. ISG12a silencing in LH86 and HLCZ03 cells increased NDV replication (Fig. 6E) . In contrast, the oncolytic effect of NDV was lower in ISG12a shRNA knockdown LH86 and HLCZ03 cells compared to scrambled-shRNA-transfected cells (Fig. 6F) , supporting the role of ISG12a in NDV oncolysis. These findings suggest that ISG12a may inhibit viral replication and mediate the oncolytic effect of NDV in cancer cells.
RIG-I contributes to ISG12a-mediated inhibition of NDV replication and oncolysis. RIG-I plays an important role in the innate immune response to viral infection (Zhu et al., 2007; Wang et al., 2008; Fournier et al., 2012; Wilden et al., 2009) . To identify the mechanisms of the regulation of viral replication and NDV oncolysis by ISG12a, we knocked down RIG-I in LH86 cells using RIG-I shRNAs. RIG-I was indeed reduced (Fig. 7A) . The production of type I IFN and ISG12a in response to NDV infection was downregulated in LH86 cells with RIG-I knockdown (Figs. 7B and C; 8C). The inhibition of NDV replication by ISG12a in LH86 cells was partially reversed by RIG-I knockdown (Fig. 7D) . In contrast, silencing of RIG-I in LH86 cells impaired the NDV oncolysis (Figs. 7E and 8C) . Forced expression of ISG12a partially reversed the decreased NDV oncolysis in RIG-I-silenced cells (Fig. 7F) . The data suggested that RIG-I contributes to ISG12a-mediated inhibition of NDV replication and oncolysis in cancer cells. 
Induction of Noxa contributes to ISG12a-mediated oncolysis
To determine the apoptotic pathway involved in NDV oncolysis, we examined caspase 9 in NDV-infected cells. Cleaved caspase 9 was observed in cells with NDV infection, indicating that NDV infection activates intrinsic apoptotic pathway (Fig. 8A) . Intrinsic apoptosis is regulated by BH-3 only proteins of Bcl-2 family (Lazar et al., 2010) . NDV infection induced Noxa in cancer cells, although the level of Puma, Bax, and Bcl-2 did not change (Fig. 8B) . Silencing of ISG12a decreased the expression of Noxa and reduced the oncolytic effect of NDV (Fig. 8C) . Silencing of Noxa by shRNA inhibited the NDV oncolysis (Fig. 8D) . However, forced expression of Noxa reversed the decreased oncolysis in ISG12a-silenced LH86 cells (Fig. 8E) . These data suggested that induction of Noxa by NDV contributes to ISG12a-mediated oncolysis.
Discussion
Elucidation of the mechanisms of oncolysis of NDV and other oncolytic viruses will extend our knowledge of the novel anticancer therapies and lead to clinical use of these viruses (Shobana et al., 2013; Zaragoza et al., 2006) . It had been pointed out that oncolytic viruses replicate selectively in cancer cells and immortalized cells because of their defective antiviral response (Wang et al., 2009 ). Ours and other recent studies have demonstrated effective oncolysis of NDV in cancer cells having an IFN response (Lazar et al., 2010; Mansour et al., 2011; Puhlmann et al., 2010; Vigil et al., 2007) . The ability of NDV to replicate in IFN-competent cells indicates that other factors may be responsible for the selectivity.
The absence of innate immune response at early time points postinfection enhanced NDV replication in advanced cancer cells and induced high level of ISG12a after 48 h pi, making it a more efficient oncolytic agent ( Figs. 2A and 4C ). On the contrary, an early type I IFN expression inhibited viral replication in well-differentiated cancer cells (Figs. 4D and 5A ), induced low level of ISG12a and less oncolytic activity of NDV after 48 h ( Figs. 2A and 4C ). We presume that the sensitivity of NDV oncolysis in advanced HCC cells may be dependent on the ability of NDV to induce high level of ISG12a. Our data showed that ISG12a significantly decreased in aggressive (advanced) cancer tissues, as compared with that of less invasive (well-differentiated) cancer tissues (Fig. 4A) . The oncolytic activity of NDV was strong in advanced TRAIL-resistant Huh7 and HLCZ01 cells compared to well-differentiated TRAIL-sensitive LH86 and HLCZ03 cells, corresponding to high induction level of ISG12a in Huh7 and HLCZ01 after 48 h pi. Forced expression of ISG12a in Huh7 and HLCZ01 cells inhibited viral RNA replication and enhanced NDV oncolysis. ISG12a silencing in LH86 and HLCZ03 cells increased NDV replication but inhibited oncolytic effect of NDV. All the data suggest that ISG12a expression may be responsible for the oncolytic effect of NDV.
The oncolytic activity of NDV in cancer cells possessing resistance to TRAIL-mediated apoptosis was partially still mediated through apoptosis. However, apoptosis induced by NDV infection was much earlier in Huh7 and HLCZ01 cells than in LH86 and HLCZ03 cells. The early apoptosis in Huh7 and HLCZ01 cells may be due to the induction of high ISG12a level and the activation of various apoptosis pathways by NDV infection. The early induction of IFN by NDV in well-differentiated LH86 and HLCZ03 cells inhibited viral replication and delayed apoptosis and oncolysis of the cells. Due to low level of endogenous ISG12a, activation of antiviral response may be deficient in Huh7 and HLCZ01 during early virus infection, allowing increased viral replication and subsequent IFN production, which would explain the higher level of IFN and ISG12a in the cells at late time points. When IFN generation is delayed and ISG12a is highly induced in advanced Huh7 and HLCZ01 cells, virus replication progresses too far to be effectively inhibited by IFN and ISG12a at later time points after infection, even with higher level of type I IFN and ISG12a in Huh7 and HLCZ01 cells compared to LH86 and HLCZ03 cells (Fig. 5A ). These data indicated that early induction of IFN rather than high level of IFN at later stage is important for resistant to NDV infection, which is consistent with one recent report (Wilden et al., 2011) .
Apoptosis is one of the intracellular innate immune responses to viral infection (Smith et al., 2013; Cary et al., 2011) . Many tumor cells have developed various strategies to inhibit apoptosis triggered by NDV infection. We proposed that the oncolytic specificity of NDV may be secondary to high level of ISG12a induced by NDV in cancer cells. After initial virus entry, the property of apoptosis resistance prolongs the cancer cells during early viral infection, producing more virus particles and inducing high level of ISG12a, causing enhanced NDV oncolysis in the cells.
The selective oncolysis of virus may be due to the deficient IFN system in the cells, while robust innate immune in normal cells prevents viral replication (Huang et al., 2012) . However, our data demonstrated that IFN signaling pathway is partially functional in cancer cells compared to that of normal cells, as evidenced by induction of IFN by NDV in cancer cells although at a lower level than in normal cells, and by inhibition of NDV replication in cancer cells by pretreatment with recombinant IFN. The ability of NDV to induce IFN may be an additional benefit for its oncolytic activity. Anticancer properties of IFN are established by its stimulated genes or through regulating innate and adaptive immunity (Matsumura et al., 2005; Smyth, 2005) . Our overall data suggest that high basal level of ISG12a in TRAIL-sensitive cells may inhibit NDV replication and oncolysis, while low basal level of ISG12a in TRAIL-resistant cells may allow sufficient NDV replication and oncolysis, and RIG-I and Noxa are required for NDV oncolysis (Fig. 9) .
Our study indicates that NDV may be used for cancer resistant to therapeutic agents such as TRAIL. Many chemoresistant tumors have been demonstrated to be related with apoptosis resistance (Ziebarth et al., 2013; Hu et al., 2012; Goldsmith et al., 2012) . NDV might render the chemoresistant cancer cells sensitive to conventional treatment, as a synergistic effect of oncolytic viruses and chemotherapeutic drugs (Meng et al., 2012) . Our findings will provide a clue for the development of oncolytic viral agents fighting against resistant tumors.
Materials and methods
Cell lines, antibodies, and reagents
Well-differentiated (pathological grade I) HCC cell lines LH86, HLCZ03 and advanced (pathological grade II, III and IV) HCC cell lines HLCZ01 and Huh7 were maintained in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen), L-glutamine, nonessential amino acid (Invitrogen) (Gyrd-Hansen and Meier, 2011; Zhu et al., 2007) . LH86 is a well-differentiated HCC cell line we had established previously (Zhu et al., 2007) . HLCZ01 cells are derived from grade II differentiated HCC tissue of a male patient . Anti-PARP antibody and mouse anti-V5 antibody were obtained from Cell Signaling Technology and Invitrogen, respectively.
An Annexin V-FITC apoptosis detection kit was purchased from BD Pharmingen (San Diego, CA). β-actin monoclonal antibody was from Sigma (St. Louis, MO).
Isolation and establishment of novel hepatoma cell line HLCZ03
The patient signed the consent forms to acknowledge participation in this study approved by the Review Board of Hunan Provincial Tumor Hospital. All procedures followed were in accordance with the Ethics Committee of Hunan Provincial Tumor Hospital. HLCZ03 cells were isolated from grade I differentiated HCC tissue of a male patient. The cells were generated as described previously . Briefly, immediately after surgical resection, the tumor tissue sample was stored in PBS, and dissociation of the cells was performed within 1 h by two-step perfusions. Visible vessels were first perfused for 15 min with Liver Perfusion Medium (Invitrogen) to eliminate the blood cells. A second perfusion was performed with collagenase-and dispase-containing Liver Digest Medium (Invitrogen) until the tissue was digested. The perfused tissue was cut into small pieces and shaken gently in Hepatocytes Wash Medium (Invitrogen). The cells and small pieces of liver tissue were cultured with DMEM/F12 medium supplemented with 10% FBS. The cell clones were picked and cultured in 6-well plates. The cells were expanded until cell growth was sufficient to fulfill the culture well. 5 Â 10 6 cells were injected into NOD/SCID mice. Three months later, tumor tissues removed from the mouse were cut into small pieces and cultured with DMEM/F12 medium. One clone was named HLCZ03.
Isolation of primary human hepatocytes (PHH)
The procedures were in accordance with the Ethics Commission of Hunan Provincial Tumor Hospital. Primary human hepatocytes (PHH) were obtained from healthy peritumoral liver resection specimens from non-HBV, non-HCV and non-HIV infected patients undergoing partial hepatectomy for primary hepatocellular carcinoma or secondary metastatic lesions due to other cancers. PHHs were isolated and cultured as described previously (Yang et al., 2011) . Virus NDV D817 strain was kindly provided by Joseph Peiris (University of Hong Kong, Hong Kong). The pellet was suspended in PBS and used for virus stock. Sucrose density-gradient ultracentrifugation was performed for purification of NDV. Huh7 cells were infected with NDV at an MOI of 0.01 for 72 h. The supernatant of NDV-infected Huh7 cells was filtered and pelleted through a 35% sucrose cushion at 28,000 rpm in a SW28 rotor (Beckman Coulter) for 16 h at 4 1C. To remove cytokines or other proteins, the pellet was resuspended in PBS containing 0.2% EDTA followed by ultracentrifugation at 80,000g for 4 h at 4 1C in a SW41Ti rotor (Beckman Coulter). After resuspension of the pellet in PBS and determination of viral titer, an aliquot of the virus stock was frozen at À 80 1C.
Tissue samples
A total of 9 snap-frozen normal liver tissues and 15 liver cancer tissues were collected at Hunan Provincial Tumor Hospital. The human tissues were obtained and studied in strict adherence to the protocol approved by Review Board of Hunan Provincial Tumor Hospital.
Construction
ISG12a cDNA was amplified from total RNA isolated from LH86 cells by standard RT-PCR, and subsequently subcloned into the expression vector pcDNA3.1/V5-His (Invitrogen). The primers for amplification of ISG12a are 5 0 -CGCGC GGATCCATGGAGGCCT-CTGCTCTC-3 0 (F), and 5 0 -CTGCAGGAATTCGTAGAACCT CGCAAT-GA-3 0 (R). The oligonucleotides encoding 19-mer hairpin sequence specific to the ISG12a mRNA were incorporated into the pSilencerneo plasmid (Ambion). The sequences of ISG12a shRNAs targeting two regions of ISG12a were 5 0 -AAGTTCATCC TGGGCTCCATT-3 0 and 5 0 -AATTAACCCGAGCAGGCATGG-3 0 . The plasmids were sequenced, and transfected into the cells using Lipofectamine 2000 reagent (Invitrogen). Knockout of ISG12a was confirmed by western blot and real-time PCR described below.
Titration of infectious virus
Titer of virus stock was calculated by using TCID50 assay prior to infection. Huh7 cells were seeded in 96-well plates and grown at 37 1C, 5% CO 2 . After the cells grew to confluence, varying dilutions of ) were added to each well. The plates were then incubated for three days. The log TCID50/ml calculation was based on Reed and Muench formula. We counted cell number and determined the MOI according to the TCID50 before each experiment.
Viral infection
The cells were plated on 6-well or 96-well plates for 24 h prior to infection. On the day of infection, the virus was added to the cells at required MOI. 2 ml of culture medium was added to the cells and the mixture was incubated at 37 1C. The supernatant was collected at indicated time points.
Caspase-3/7 assay
The cells were infected with NDV at required MOI in 96-well plates. Caspase-3/7 activity in the cells was measured using a Caspase-3/7 assay kit (Promega, Madison, WI) according to the manual. Caspase-3/7 activity was measured and normalized with the control.
Flow cytometry analysis
The procedure was described previously (Zhu et al., 2007) . The cells were infected with NDV and analyzed by the Annexin V-FITC apoptosis detection kit. The data were analyzed with the CellQuest software.
Animal experiments
Six to seven week old mice (four per group) were inoculated subcutaneously (s.c.) to the mouse flank with HCC cells (1 Â 10 6 per 0.2 ml) to develop tumor. About 14 days post-tumor cells implantation, mice were treated either by NDV (10 7 PFU per dose) or PBS by i.v. administration every 4 days. Tumor volume was calculated on the basis of the formula V ¼(L Â W 2 )/2 (L, length and W, width).
IFN induction bioassay
The cells were infected with NDV and the supernatant was collected. Virus in the supernatant was UV inactivated. Huh7 cells were incubated overnight with the inactivated supernatant. The supernatant from uninfected cells or cells treated with 100 units of IFN-α (Roche, Basel, Switzerland) was used as negative or positive control, respectively. The cells were washed and subsequently infected with NDV at an MOI of 0.01. The level of NDV and IFN-β was determined by real-time PCR with NDV and human IFN-β-specific primers, respectively. All bioassay experiments were performed in at least triplicate to confirm the results.
ELISA
The supernatant from viral-infected cells in culture was collected at different times postinfection, and an IFN-β enzymelinked immunosorbent assay (ELSIA) kit (PBL Biomedical Laboratories) was used to detect IFN-β protein in the supernatant according to the manufacture's protocol.
MTS assay
The protocol was reported previously . Briefly, one day before NDV infection, 1.0 Â 10 3 cells were seeded in triplicate in a 96-well plate. The cells were cultured with or without NDV infection at various time points at 37 1C. 20 μl of the CellTiter AQ Solution containing MTS and an electron coupling reagent (Promega, Madison, WI) was added to each well. After 2 h incubation at 37 1C, the absorbance at 490 nm was measured. The cell viability was calculated with respect to the control samples. At least three independent experiments were performed.
Western blot analysis
The procedure was published previously (Shi et al., 2014) .
Real-time PCR assays
Total cellular RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA). Superscript II First-Strand Synthesis Kit and Quantitative PCR SuperMix-UDG were purchased from Invitrogen. The primers targeting GAPDH had been reported and real-time PCR was performed as described previously Shi et al., 2014) . The primers for ISG12, IFN-β, RIG-I and NDV are listed below. 
Statistical analysis
The data are presented as means 7 S.D. The data were analyzed using two-tailed Student's t-test.
n P o0.05, nn P o0.01, nnn Po 0.001.
